Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson's disease. (2022)

• Record Type: Journal Article
• Authors: Oka, Hisayoshi; Sengoku, Renpei; Nakahara, Atsuo; Yamazaki, Mikihiro
• Is Part Of: Clinical parkinsonism & related disorders. Volume 6(2022)
• Publication Date: 2022
• Subjects: Rasagiline -- Orthostatic hypotension -- 24-hour ambulatory BP monitoring -- Daily BP fluctuation -- Parkinson's disease; Parkinson's disease -- Periodicals; Movement disorders -- Periodicals; 616.833005
• DOI: 10.1016/j.prdoa.2021.100124
• Languages: English
• ISSNs: 2590-1125

Abstract

Highlights: Blood pressure dysregulation is important in Parkinson's disease. Anti-Parkinsonian drugs that have less effect on blood pressure should be used. Some monoamine oxidase B inhibitor may cause orthostatic hypotension. Rasagiline does not exacerbate orthostatic hypotension and nocturnal blood pressure. Rasagiline is a suitable medication for early or mild Parkinson's disease. Abstract: Introduction: Orthostatic hypotension (OH) and abnormal blood pressure (BP) fluctuations occur mainly due to noradrenergic dysfunction and are clinically important in patients with Parkinson's disease (PD). They lead to impairments of cognition function, daily activities, and quality of life. Some monoamine oxidase (MAO)-B inhibitors have a sympathomimetic amine, which can be attributed to OH. Therefore, we determined whether rasagiline, a common MAO-B inhibitor used in PD treatment, can contribute to cardiovascular autonomic BP dysregulation in patients with early or mild PD. Methods: Nineteen patients with early or mild PD were recruited, and tilt test and 24-h ambulatory BP monitoring (ABPM) were performed before and after rasagiline administration. Early or mild PD was defined as patients with de novo (n = 4), levodopa (n = 10), dopamine agonist (n = 1), levodopa and one dopamine agonist (n = 2), levodopa and droxidopa (n = 1), and levodopa and istradefylline (n = 1). Furthermore, patients with motor fluctuation and multiple dopamine agonists were excluded from our study. Results: OH and BP frequency were not significantly exacerbated before or after rasagiline administration. No significant differences of type in BP fluctuation on ABPM and the degree of nocturnal BP falls were found before and after rasagiline administration. The Unified Parkinson's Disease Rating Scale motor score in patients (post-rasagiline administration) was significantly improved compared with before. Conclusion: Rasagiline seems to be a suitable medication for Parkinsonian symptoms in patients with early and mild PD. It does not exacerbate cardiovascular autonomic responses, circadian rhythm of BP, or both.